IDH1 and central nervous system cancer: Instead, more precise endpoints such as "molecular remission" (e.g., clearance of IDH mutations and decrease in 2-HG levels) and "imaging remission" (e.g., prolonged progression-free survival of glioma) were incorporated into the assessment system.